Table 4.
Associations between IgE sensitization, serum specific IgE scores and risk of site-specific cancers by sex with chronological age as timescale.
| HR (95% CI) |
||||||||
|---|---|---|---|---|---|---|---|---|
| IgE sensitization |
Specific IgE scores§ |
|||||||
| n cancer | No | Yes | 0 | 1–2 | 3–4 | 5–6 | Ptrend | |
| Both men and women | ||||||||
| All excluding NMSC | 664 | 1.0 (Ref) | 0.82 (0.69–0.99) | 1.0 (Ref) | 0.96 (0.78–1.18) | 0.67 (0.52–0.85) | 0.81 (0.48–1.36) | 0.005 |
| Colorectal | 64 | 1.0 (Ref) | 0.71 (0.39–1.26) | 1.0 (Ref) | 0.75 (0.38–1.51) | 0.60 (0.27–1.34) | 1.23 (0.28–5.42) | 0.32 |
| hematological | 53 | 1.0 (Ref) | 0.95 (0.51–1.76) | 1.0 (Ref) | 1.16 (0.58–2.30) | 0.66 (0.27–1.59) | 1.22 (0.27–5.46) | 0.62 |
| Melanoma | 37 | 1.0 (Ref) | 0.53 (0.24–1.17) | 1.0 (Ref) | 0.79 (0.33–1.88) | 0.32 (0.09–1.13) | N/A | 0.04 |
| Pulmonary | 35 | 1.0 (Ref) | 0.87 (0.41–1.84) | 1.0 (Ref) | 1.24 (0.56–2.76) | 0.41 (0.11–1.43) | 0.94 (0.12–7.44) | 0.33 |
| Bladder | 25 | 1.0 (Ref) | 1.20 (0.50–2.87) | 1.0 (Ref) | 1.45 (0.56–3.77) | 0.95 (0.29–3.14) | N/A | 0.89 |
| NMSC | 25 | 1.0 (Ref) | 0.97 (0.40–2.39) | 1.0 (Ref) | 0.62 (0.17–2.20) | 1.56 (0.55–4.44) | N/A | 0.74 |
| Kidney | 21 | 1.0 (Ref) | 1.09 (0.40–2.95) | 1.0 (Ref) | 1.50 (0.52–4.30) | 0.27 (0.03–2.23) | 3.42 (0.63–18.50) | 0.95 |
| CNS | 20 | 1.0 (Ref) | 1.33 (0.47–3.73) | 1.0 (Ref) | 1.82 (0.62–5.33) | 0.88 (0.21–3.61) | N/A | 0.74 |
| Men | ||||||||
| All excluding NMSC | 267 | 1.0 (Ref) | 0.89 (0.68–1.16) | 1.0 (Ref) | 0.95 (0.69–1.31) | 0.80 (0.57–1.13) | 1.12 (0.55–2.28) | 0.37 |
| Prostate | 97 | 1.0 (Ref) | 0.93 (0.38–1.04) | 1.0 (Ref) | 0.86 (0.50–1.48) | 0.93 (0.53–1.63) | 2.31 (0.78–6.82) | 0.79 |
| Colorectal | 35 | 1.0 (Ref) | 0.71 (0.34–1.49) | 1.0 (Ref) | 0.77 (0.31–1.88) | 0.54 (0.19–1.53) | 1.83 (0.38–8.77) | 0.52 |
| hematological | 23 | 1.0 (Ref) | 1.13 (0.44–2.89) | 1.0 (Ref) | 1.11 (0.36–3.35) | 1.12 (0.35–3.62) | 1.35 (0.15–12.15) | 0.78 |
| Pulmonary | 15 | 1.0 (Ref) | 1.07 (0.35–3.26) | 1.0 (Ref) | 1.41 (0.42–4.71) | 0.57 (0.11–3.02) | 2.38 (0.24–23.99) | 0.93 |
| Melanoma | 12 | 1.0 (Ref) | 0.56 (0.15–2.06) | 1.0 (Ref) | 0.65 (0.13–3.18) | 5.31 (0.10–2.77) | N/A | 0.31 |
| Women | ||||||||
| All excluding NMSC | 397 | 1.0 (Ref) | 0.81 (0.63–1.03) | 1.0 (Ref) | 0.98 (0.75–1.28) | 0.57 (0.39–0.83) | 0.65 (0.30–1.42) | 0.008 |
| Breast and gynecological | 218 | 1.0 (Ref) | 0.76 (0.55–1.06) | 1.0 (Ref) | 0.85 (0.58–1.24) | 0.68 (0.43–1.10) | 0.36 (0.09–1.47) | 0.04 |
| Breast | 165 | 1.0 (Ref) | 0.83 (0.57–1.20) | 1.0 (Ref) | 0.95 (0.63–1.45) | 0.69 (0.40–1.19) | 0.49 (0.12–2.05) | 0.14 |
| Gynecological | 53 | 1.0 (Ref) | 0.55 (0.27–1.13) | 1.0 (Ref) | 0.54 (0.22–1.32) | 0.65 (0.25–1.64) | N/A | 0.11 |
| Colorectal | 29 | 1.0 (Ref) | 0.75 (0.29–1.91) | 1.0 (Ref) | 0.75 (0.25–2.26) | 0.84 (0.23–3.10) | N/A | 0.53 |
| Hematological | 30 | 1.0 (Ref) | 0.83 (0.37–1.88) | 1.0 (Ref) | 1.13 (0.48–2.71) | 0.37 (0.08–1.65) | 1.10 (0.14–8.82) | 0.40 |
| Melanoma | 25 | 1.0 (Ref) | 5.13 (0.19–1.42) | 1.0 (Ref) | 0.86 (0.30–2.43) | 0.18 (0.02–1.49) | N/A | 0.07 |
§
Highest specific IgE scores recorded at baseline.
N/A = not applicable; n = number of participants; NMSC = nonmelanoma skin cancer; CNS = central nervous system.
All models were adjusted for sex (except for sex-specific analysis), socioeconomic status, period of measurement, history of chronic pulmonary disease and serum total IgE.